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Introduction
Autism spectrum disorder (ASD) is character-
ized both by impairments in social communication and 
relationships and by the presence of impairing restricted 
and repetitive patterns of behavior, interests, or activi-
ties.1 Though some level of impairment must be present 
before 3 years of age, individuals vary greatly in terms of 
symptom expression and level of functioning. Up to one 
half of individuals are functionally nonverbal.2 Further, a 
significant proportion of affected individuals have gen-
eral cognitive and functional abilities consistent with in-
tellectual disability.3 Repetitive behaviors may interfere 
with learning and activities of daily living. In addition 
to these defining symptoms, neurocognitive issues with 
abstraction and generalization, alexithymia (difficulty 
identifying feelings) and poor understanding of others’ 
emotions and cognitions (known as theory of mind) are 
common. Many affected individuals require close su-
pervision to accomplish activities of daily living and/or 
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Diagnosis and treatment of comorbid neuropsychiatric 
illness is often a secondary focus of treatment in indi-
viduals with autism spectrum disorder (ASD), given that 
substantial impairment may be caused by core symp-
toms of ASD itself. However, psychiatric comorbidi-
ties, including depressive disorders, are common and 
frequently result in additional functional impairment, 
treatment costs, and burden on caregivers. Clinicians 
may struggle to appropriately diagnose depression in 
ASD due to communication deficits, atypical presenta-
tion of depression in ASD, and lack of standardized 
diagnostic tools. Specific risk and resilience factors for 
depression in ASD across the lifespan, including level 
of functioning, age, family history, and coping style, 
have been suggested, but require further study. Treat-
ment with medications or psychotherapy may be ben-
eficial, though more research is required to establish 
guidelines for management of symptoms. This review 
will describe typical presentations of depression in in-
dividuals with ASD, review current information on the 
prevalence, assessment, and treatment of comorbid 
depression in individuals with ASD, and identify impor-
tant research gaps.            
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maintain safety. Commonly associated medical problems 
such as epilepsy and bowel dysfunction and psychiatric 
problems with attention, mood, anxiety, and impulse con-
trol increase functional impairment, costs, and burden on 
caregivers.4-9 Recent studies by the Centers for Disease 
Control and Prevention (CDC) found that 1 in 68 8-year-
old children had a prior medical or educational diagnosis 
of ASD.10 A population-based clinical screening study 
found that 2.6% of 7- to 12-year-olds in Korea were af-
fected, two thirds of whom had not been previously diag-
nosed.11 Thus, ASD represents a significant public health 
concern due to high prevalence, early onset, marked dis-
ability, and lifelong persistence. 
 The annual prevalence of depressive disorders in the 
general population is approximately 10%, with rates of 
7.5% among adolescents. Depression itself carries an 
increased risk of medical illness, poor functioning in 
adolescence and adulthood, and death due to suicide.12 
Studies of comorbid psychiatric illness in ASD indicate 
high rates of depressive disorders,13,14 though they are 
often under-recognized and likely undertreated. Di-
agnosis of Major Depressive Disorder (MDD) in the 
context of ASD can be particularly challenging given 
atypical presentations of depression in ASD, masking of 
common depression symptoms by features of ASD, and 
the lack of standardized diagnostic tools for assessment 
of depression in those with ASD. Little is known about 
the presentation, risk factors, and course of depressive 
illness over time as youth with ASD enter adulthood.15 
Recognition of a comorbid depressive illness has im-
portant implications for overall treatment, prognosis, 
and service delivery.14 This review will describe typical 
presentations of depression in ASD, review available 
information on the prevalence, assessment, and treat-
ment of depression in individuals with autism across the 
lifespan, and identify the critical gaps in our knowledge.
Presentation of depression in ASD
Two case vignettes are presented below, to highlight the 
key challenges in diagnosing comorbid depression in 
ASD. The first involves a verbal young adult. The sec-
ond involves a minimally verbal school-aged child.
Case 1: Jack
Jack had been diagnosed with ASD at 30 months of age 
and developed phrase speech at 8 years of age. He was 
particularly interested in popular music and physical fit-
ness, interacted around these interests with family and 
adults in the neighborhood, and was very insistent on 
following his routines, but had never been aggressive. 
Nine months before he came to the clinic, he had gradu-
ated from high school at age 22 and had begun working 
with a job coach at a local grocery store. His younger 
brother had also graduated and moved away to college. 
Things went well for the first few months, but then he 
began to have difficulty sleeping and was eating less. He 
began exercising for more extended periods and com-
plained to his parents that his muscles were melting. He 
began to check his appearance in mirrors so frequently 
that it interfered with his daily activities. At the same 
time, he was more withdrawn and seldom talked with 
the neighbors any more. He was in almost constant 
motion, pacing, playing basketball or walking the dog. 
He also was more irritable and on occasion pushed fur-
niture over when he felt others were interfering with 
his activities. On mental status exam, he spoke very 
little and often seemed preoccupied or confused. When 
asked about his mood he said “not good” and talked 
about his muscles. He said there was a black shadow 
coming over his arms and legs and he was not himself. 
His affect was irritable especially when asked direct 
questions. He denied any desire to hurt himself or oth-
ers. He did not respond to questions about the duration 
of his problems, things that he enjoyed, or things that 
may have been upsetting. His parents were primarily 
concerned about his withdrawal, irritability and agita-
tion. Family history was positive for schizophrenia, de-
pression, and severe anxiety. His parents were reluctant 
to try an antipsychotic medication and he was started 
on fluoxetine. Within 3 months he was sleeping better, 
and was less physically agitated and less irritable. He no 
longer looked in the mirror or talked about his muscles. 
However, he remained more withdrawn than his base-
line for 4 more months despite increases in his fluox-
etine. After 1 year, his family and he felt he was back to 
his usual self. 
Case 2: Mark
Mark had been diagnosed with ASD at age 2 and had 
always been in a self-contained class. His tested cogni-
tive abilities were in the severely intellectually disabled 
range, and he was minimally verbal. He had almost 
constant self-stimulatory behaviors, but could sit in the 
220
Management of depression in ASD - Chandrasekhar and Sikich Dialogues in Clinical Neuroscience - Vol 17 . No. 2 . 2015
classroom for up to 40 minutes at a time and was able to 
complete about 80% of the work his teachers gave him. 
He would bang his head every few days when frustrated 
at his baseline and would sometimes become physically 
aggressive if people tried to restrain him. He was a very 
picky eater, had chronic constipation, and had always 
been a poor sleeper. There was a family history of de-
pression with good response to bupropion. 
 When he was 9 years old, Mark’s teachers, who had 
worked with him the previous year, expressed concern 
that something was wrong. He was resistant to doing 
more than 5 minutes of academic work, and would re-
spond aggressively or start banging his head if pushed to 
do so. He seemed very easily annoyed by his classmates 
and was often aggressive to them for no clear reason. 
At home, he was also more unpredictable and was not 
soothed by activities or foods that he usually desired. He 
cried more often, would bang his head multiple times a 
day, and woke multiple times a night. Repeated physi-
cal exams failed to reveal any medical problems that 
might account for the change in his behavior. A bowel 
cleanout was performed, with no change in behavior. 
There was minimal improvement with an antipsychotic 
targeting his aggression and self-injury. However, the 
episodes of aggression and head banging were reduced 
by ~60% after 2 months of treatment with bupropion. 
His sleep returned to normal, crying was minimal, and 
his mother reported he seemed happier. 
Clinical presentation
Common features of depression, including dysphoric 
mood, anhedonia, and sad affect may be difficult to rec-
ognize in people with ASD. Relatively few individuals 
with ASD directly express feelings of sadness, hope-
lessness, low self-esteem, worthlessness, excessive guilt, 
or suicidal ideation.16,17 Further, individuals with ASD 
often have flat or constricted affect, so that changes as-
sociated with the presence of depression may be sub-
tle. Early case reports of depression in ASD included 
reports of two individuals who cried for the first time 
in their lives, and others who appeared apathetic and 
unhappy.18 Anhedonia may present as decreased inter-
est in preferred interests, refusal to attend structured 
activities, or decreased response to previously motivat-
ing items or activities. The content of written or drawn 
communications may become increasingly morbid or 
morose, for example a child drawing tombstones in-
stead of a preferred subject. Some individuals may ex-
perience a regression in self-care abilities, presenting 
with worsening hygiene or general appearance.18,19 In 
other cases there may be apparent worsening of core 
features of ASD, including social withdrawal and in-
sistence on sameness, or worsening of symptoms fre-
quently associated with ASD such as concentration 
deficits, agitation, aggression, or self-injury.16,18,20 Neuro-
vegetative symptoms such as sleep disturbance, changes 
in appetite or weight, and psychomotor retardation or 
agitation are common, and may be the most prominent 
signs in minimally verbal individuals. Psychotic or po-
tentially psychotic symptoms may also herald the onset 
of depression. If psychotic symptoms are present, they 
may reflect communication difficulties, psychosis in the 
context of depression, or a primary psychotic illness. In 
all cases, the clinician should be focused on differences 
between the patient’s baseline affect and behaviors and 
his/her current presentation.
Prevalence
It is widely accepted that depressive disorders occur 
frequently in ASD, though there is much variation in 
the estimated prevalence. Published 1-year prevalence 
rates for concurrent depression in youth with ASD 
range from 0.9% to 50%, with lifetime prevalence rates 
of depression among youth with ASD estimated to 
range from 10.1% to 53%.15,21-23 In the Interactive Au-
tism Network database, which consists of unconfirmed 
parent reports of symptoms and diagnoses, 11% of 4343 
children had been diagnosed with depression.23 Fairly 
similar results were obtained by Leyfer and colleagues 
who directly interviewed parents of children and ado-
lescents between the ages of 5 and 17 years (n=109, 
mean age 9 years) with confirmed ASD using a version 
of the Kiddie Schedule for Affective Disorders and 
Schizophrenia that had been modified to account for 
possible differences in symptom presentation among 
youth with ASD, known as the Autism Comorbidity In-
terview (ACI). Specifically 10% of the participants met 
DSM-IV criteria for MDD, and an additional 14% qual-
ified for subsyndromal depression.2 Studies that have 
directly compared youth with ASD with those with typ-
ical development or similar cognitive impairments have 
found that those with ASD are significantly more likely 
to experience an episode of any psychiatric illness, most 
commonly MDD, and that their depressive episodes 
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tend to last longer.24,25 The largest such study, conducted 
by Mayes and colleagues, examined parent ratings on 
the Pediatric Behavior Scale in 350 youth with ASD, 
187 typically developing peers and 853 children with 
other disorders, and similarly found significantly higher 
rates and severity of depressive symptoms among the 
youth with ASD compared with either control group.17
 The degree to which prevalence data for depression 
in children and adolescents can be applied to adults is 
unclear. The results of existing studies are inconsistent 
with both lower and higher rates of depression being 
reported in adults than in the pediatric population with 
ASD. A longitudinal study that followed 89 partici-
pants over ~16 years found a modest reduction in emo-
tional and behavioral problems associated with ASD 
over time, including in the study’s proxy measure of 
depression.25 In contrast, two independent studies that 
solicited the involvement of all adults identified with 
an ASD from specific regions in Sweden and Norway 
respectively found higher rates of depression (37% to 
70%) than reported by many other groups for young-
er individuals with ASD.26,27 Consistent with studies in 
children with ASD, adults with ASD seem more vulner-
able to depression those with other developmental dis-
abilities or typically developing individuals. 
Potential risk and resilience factors for 
depression in ASD
The role of specific vulnerability factors for depression 
in ASD requires more study, though some important 
patterns have emerged. Family history of depression, 
including in second-degree relatives, appears to in-
crease risk for depression in ASD, while family history 
of ASD does not.28 Further, comorbid depression can 
frequently be related to a major negative life event in-
cluding significant losses, transitions in caregivers, or 
changes in structure or activities.14,29 
 The role of IQ in the development of depression in 
ASD is an area of active examination. Individuals with 
high-functioning ASD are often assumed to be more 
vulnerable to depressive disorders than their lower-
functioning peers, perhaps due to relative strengths in 
social awareness, and greater expectations of fitting in 
with their peers. Many of these studies have focused on 
verbally fluent individuals with ASD and/or have relied 
on parent report of symptoms. One study that exam-
ined 95 youths 6 to 18 years old with intelligence quo-
tients (IQs) ≥70 did not find any relationship between 
IQ and depression.30 In contrast, the much larger study 
by Mayes et al, which included 233 high-functioning 
children (IQ ≥ 80), and 117 low-functioning children 
(IQ <80), found that the children with high-functioning 
ASD were significantly more depressed by parent re-
port than low-functioning children. Additionally, high-
functioning children were reported to have significantly 
lower self-esteem than low-functioning and typically 
developing children.17 This is consistent with multiple 
studies in verbal adults that have found that those with 
higher cognitive ability, less social impairment, more 
self-perceived impairment, and higher rates of other 
psychiatric symptoms, such as anxiety and rumination, 
were more likely to report depressive symptoms.19,31-33 
Similarly, adults with low-functioning ASD appear less 
likely to be identified with depression than their high-
functioning peers.34 It is unclear to what extent high-
functioning individuals with ASD are actually more 
vulnerable to depression than their lower-functioning 
peers and to what extent depression is more easily 
identified in verbal and more insightful individuals with 
ASD. It seems likely that lower-functioning individuals 
may be unable to self-report depressive symptoms and 
instead engage in increased self-injury or aggressive or 
destructive behavior or demonstrate increased social 
withdrawal or rigidity during periods of depression.34 
Such externalizing behaviors may overshadow internal-
izing symptoms.19 
 Many people have hypothesized that greater so-
cial desire, coupled with limited social skills and more 
frequent negative social interactions and/or higher 
frequency of bullying or rejection, may be associated 
with greater risk of depression among individuals with 
ASD. However, we are unaware of any studies specifi-
cally examining these factors with respect to incidence 
of depression. Similarly, it has been hypothesized that 
individuals with greater theory of mind difficulties, spe-
cifically difficulties appreciating the mental states of self 
and others and using this knowledge to understand and 
predict behavior, might experience more social rejec-
tion and subsequently more depressive symptoms than 
those with better theory of mind abilities.35 The one 
study that specifically examined theory of mind score 
and depressive symptoms did not find any correlation; 
however, it is possible this finding is more reflective of 
difficulty recognizing and expressing one’s own feelings 
of sadness.36
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 In contrast, reduced self-esteem and the individ-
ual’s perception of one’s own impairments resulting 
from ASD have been associated with increased risk 
for depression. Interestingly, there was no correla-
tion between clinician assessments of impairment and 
depressive symptoms.37 Findings are similar in studies 
of children with ASD; those with lower levels of self-
perceived social competence endorsed higher levels of 
depressive symptoms.38 Greater rumination on one’s 
perceived impairments and lower perceived social sup-
port were also associated with increased depressive 
symptoms.37 Rumination appears closely related to re-
petitive behaviors seen in ASD, particularly insistence 
on sameness, implying that individuals may essentially 
“get stuck” on psychological substrates in addition to 
interests, rituals, and routines. Similarly, rumination has 
been found to prospectively predict the number and 
duration of major depressive episodes in typically de-
veloping adults.39 
 Boys with ASD who utilized adaptive coping strat-
egies such as seeking social support or working with 
others to solve a problem reported fewer symptoms of 
depression, while those who utilized maladaptive tech-
niques such as acting out were more likely to report 
depression, supporting concerns that externalizing be-
haviors may be linked to underlying depression. Inter-
estingly, youth with ASD who utilize avoidant coping 
styles such as cognitive restructuring, distraction, and 
ignoring reported lower symptoms of depression,40 sug-
gesting that these particular styles may be protective. 
Assessment
It is essential to obtain a good description of an individu-
al’s baseline range of emotional expression and activities 
in order to assess sustained changes in affect and behav-
ior over time.18 In addition, it is important to get a good 
history of changes in the environment that may have 
precipitated a depression and of a family history of de-
pression. Semistructured interviews designed for other 
populations or caregiver report measures may need to be 
modified or supplemented for the ASD population.41,42 
The ACI is one example of a modified screening tool.2 
During interviews it is particularly important to deter-
mine if a particular concept, such as guilt, is understood 
before inquiring about symptoms related the concept (eg, 
excessive guilt). Other concepts included in many self-re-
port measures that are particularly vulnerable to limited 
insight and communication abilities are lack of pleasure, 
pessimism, a sense of failure, or loss of energy.41,42 Care-
giver reports are also likely to be influenced by the scale 
utilized, the psychological sophistication of the reporter, 
and the degree to which the individual with ASD reveals 
his or her internalizing symptoms. Depressive symptoms 
may not be directly expressed, leading parents or care-
givers to underestimate the extent to which depression 
may be impacting functioning. This was demonstrated in 
a study of high-functioning adolescents with ASD who 
reported more symptoms of anxiety or depression than 
their parents.43 
Treatment
The role of psychopharmacological agents and psycho-
social interventions to treat depression in ASD popula-
tions requires further study. Psychotropic medications 
are frequently prescribed to youth and adults with ASD, 
and polypharmacy is common. Of a group of 33 565 chil-
dren with ASD, 64% were prescribed one psychotropic 
medication, 35% were prescribed two or more classes 
of psychotropic medication, and 15% used medications 
from three or more classes. Antidepressants were used 
in 66% of those receiving more than one class of psy-
chotropic medication.44 Psychotropic medication use 
appears to be even more common in adults with ASD 
than in children.45,46 Further, antidepressant use appears 
increased among those with high-functioning ASD.47,48 
 Treatment for depression with antidepressant agents, 
typically selective serotonin reuptake inhibitors (SSRIs), 
is guided by evidence in typically developing individu-
als. Although multiple studies have failed to demonstrate 
the efficacy of SSRIs for improving core symptoms or 
repetitive behaviors in ASD, to date no studies exist to 
determine the efficacy of SSRIs in treating comorbid 
depression in youth or adults with ASD.49,50 A Cochrane 
review of use of antidepressants recommended use of 
SSRIs for depression on a case-by-case basis.51 However, 
clinical experience suggests that these agents are useful 
and generally safe, though individuals with ASD may be 
especially prone to adverse effects such as behavioral 
activation, irritability, akathisia, and sleep disturbance.52 
Although it is not known how frequently severe irritabil-
ity symptoms in youth with ASD reflect depression, the 
FDA has approved two atypical antipsychotic medica-
tions (risperidone and aripiprazole) to treat irritability 
associated with ASD.53 
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 There is also some evidence that behavioral thera-
pies may reduce depressive symptoms in ASD. The 
most widely used of these is cognitive behavioral 
therapy (CBT), though its efficacy in treating depres-
sive symptoms has only been studied to a limited ex-
tent. CBT may be useful to modify maladaptive coping 
strategies, restructure negative thoughts, and modify 
cognitive inflexibility. Most CBT programs were de-
signed for typically developing youth and subsequently 
adapted for the ASD population. Many programs fo-
cus on anxiety, aggression, or core deficits rather than 
on depression alone,54 though these factors are likely 
closely linked. A small study of group CBT focused on 
identifying feelings, thoughts, and behaviors, expressing 
feelings appropriately, and using cognitive restructur-
ing and stress reduction techniques found a significant 
reduction in depressive symptoms compared with the 
waitlist control group after nine sessions. The observed 
improvement was sustained at 3- and 9-month follow-
up assessments.55
 Mindfulness-based therapies may also prove to be 
a useful therapeutic technique to reduce depression in 
ASD populations. This method encourages individuals 
to identify feelings or thoughts in the present moment 
and accept them, as they appear without analysis or dis-
cussion,56 an approach that may be well suited to those 
with theory of mind and communication deficits. One 
randomized controlled trial of adults with ASD found 
a significant reduction in depression, anxiety, and ru-
mination in the intervention group compared with the 
control group.57 In addition, social and vocational skills 
programs may reduce depressive symptoms in adoles-
cents and adults with ASD, even though they are not 
focused on depressive symptoms. Investigators found 
that participation in an 8-week structured group inter-
vention resulted in lower scores on the Beck Depres-
sion Inventory-II, though the effect size was small. In-
dividuals appeared to benefit from meeting others with 
similar challenges and initiating connections with each 
other outside of the group.58 
 The role of family therapy interventions in ASD is 
an area of recent but active study, as family systems are 
often profoundly affected by the impairments associ-
ated with ASD. Researchers are beginning to under-
stand the complex and bidirectional influences a family 
member with ASD has on individual family members, 
including siblings, and the family system as a whole. It 
is understood that high levels of parental psychopathol-
ogy or stress appear to predict increased ASD symp-
tom severity and emotional or behavioral symptoms 
in typically developing siblings.59 Further, high levels 
of expressed emotion or criticism in families appear 
to worsen internalizing and externalizing behaviors, as 
well as core features of ASD.60 We are not aware of any 
formal programs that utilize family therapy as a com-
ponent of treatment for depression in ASD; however 
programs that build on existing strengths and provide 
psychoeducation and support to family systems may be 
extremely useful in not only reducing family stress and 
improving quality of life, but also in improving behavior 
problems over time in children, adolescents, or adults 
with ASD. 
Research priorities
Although it is clear that depression is an issue for 
individuals with ASD, relatively little rigorous infor-
mation is available to evaluate the true scope of the 
problem or appropriate treatment and management 
of depression in this large segment of the population. 
It will likely be useful to conduct larger population-
based cross-sectional studies and longitudinal studies 
that use assessment measures modified for individuals 
with autism in order to more accurately determine the 
true prevalence of comorbid depression in ASD across 
the lifespan. Such studies would also provide more in-
formation about typical presentations of depression, 
particularly among those with more limited commu-
nication skills and insight into their own feelings. In 
addition, it is essential that we evaluate specific phar-
macologic and behavioral treatments for individuals 
with comorbid ASD and depression. Studies of SSRIs 
in individuals selected on the basis of comorbid de-
pression and ASD seem especially important. These 
studies should include some focus on minimally verbal 
individuals since they are less likely to benefit from 
the available psychological interventions.
Conclusions
In summary, depression appears to occur with greater 
frequency among people with ASD than in the general 
population. There are suggestions that the risk for co-
morbid depression increases with age. Although cur-
rent studies suggest that high-functioning, verbal indi-
viduals with ASD may be at higher risk, it is unclear 
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to what degree this finding is an artifact of current 
assessment tools and limited communication abilities 
of lower-functioning individuals. Therefore clinicians, 
parents, and caregivers must recognize that depression 
may present with a myriad of symptoms other than dys-
phoric mood in persons with ASD. Depression should 
be considered when individuals with ASD experience 
a significant change in their level of functioning or an 
increase in maladaptive behaviors. Clinicians who are 
unaccustomed to diagnosing or treating ASD popula-
tions may be poorly equipped to tease apart features 
of ASD from a comorbid depressive illness. In turn, 
individuals with marked communication and theory of 
mind deficits may struggle to report depressive symp-
toms. Nonetheless, these symptoms may carry substan-
tial additional morbidity and even potential mortality 
due to suicide,61,62 that necessitates rapid recognition 
and treatment. Standardized tools are needed to assist 
clinicians in the diagnosis of depression among those 
with ASD, and more research is needed to elucidate 
effective psychopharmacologic and psychosocial treat-
ment strategies.  o 
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Desafíos en el diagnóstico y tratamiento de la 
depresión en los trastornos del espectro autista a 
lo largo de la vida
En los sujetos con un trastorno del espectro autista 
(TEA) el diagnóstico y tratamiento de la enfermedad 
neuropsiquiátrica comórbida es a menudo un foco se-
cundario de la terapia, dado que el deterioro principal 
puede estar causado por los síntomas nucleares del 
TEA propiamente tal. Sin embargo, las comorbilidades 
psiquiátricas, incluyendo los trastornos depresivos, son 
comunes y frecuentemente se traducen en adicionales 
deterioros funcionales, costos del tratamiento y carga 
para los cuidadores. Los clínicos pueden tener dificul-
tades para diagnosticar adecuadamente la depresión 
en el TEA debido a los déficits de comunicación, la pre-
sentación atípica de la depresión en el TEA y la falta 
de herramientas diagnósticas estandarizadas. Si bien se 
han sugerido factores de resiliencia y riesgo específico 
para la depresión en el TEA a lo largo de la vida como 
el nivel de funcionamiento, la edad, la historia familiar 
y el estilo de adaptación, se requiere de más estudio. 
El tratamiento medicamentoso o la psicoterapia pueden 
ser útiles, aunque se requiere de más investigación para 
establecer guías de manejo de los síntomas. Este artícu-
lo describe las presentaciones típicas de la depresión en 
sujetos con TEA, revisa la información actualizada sobre 
la prevalencia, evaluación y tratamiento de la depresión 
comórbida en estos individuos e identifica importantes 
vacíos de la investigación.   
Les enjeux du diagnostic et du traitement de la 
dépression dans les troubles autistiques au long 
de la vie
Le diagnostic et le traitement des maladies neuropsychia-
triques comorbides sont souvent un axe secondaire du 
traitement des individus ayant un trouble du spectre de 
l’autisme (TSA), une détérioration importante pouvant 
être causée par les symptômes de fond du TSA lui-même. 
Cependant, les comorbidités psychiatriques, dont les 
troubles dépressifs, sont courantes et entraînent fréquem-
ment un handicap fonctionnel supplémentaire, des coûts 
pour les traitements et une charge pour les soignants. Il 
est parfois difficile pour les médecins de diagnostiquer 
de façon adéquate la dépression dans les TSA à cause des 
déficits de communication, de la présentation atypique de 
la dépression et du manque d’outils diagnostiques stan-
dardisés. Les risques spécifiques et les facteurs de résilience 
pour la dépression dans les TSA au long de la vie, y com-
pris le niveau de fonctionnement, l’âge, les antécédents 
familiaux et le mode d’adaptation ont été suggérés, mais 
nécessitent d’être étudiés. Des traitements médicamen-
teux ou psychothérapiques peuvent être bénéfiques, mais 
il faut d’autres recherches pour établir des recommanda-
tions pour la prise en charge des symptômes. Cet article 
décrira les présentations typiques de la dépression chez les 
personnes atteintes de TSA, reconsidèrera l’information 
actuelle sur la prévalence, l’évaluation et le traitement de 
la dépression comorbide chez les personnes atteintes de 
TSA et identifiera les lacunes importantes de la recherche. 
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